Kucukkolbasi, H.Kucukkolbasi, S.Ayyildiz, H. F.Dursun, R.Kara, H.2020-03-262020-03-2620130043-3144https://hdl.handle.net/20.500.12395/29485Objective: This study aimed to determine a possible correlation between oral mucosal disease and salivary concentrations of the antimicrobial peptides human beta-defensin-1 (h beta D-1) and human beta-defensin-2 (h beta D-2). Method: The present work focussed on the establishment of a reversed phase-high performance liquid chromatography (RP-HPLC) procedure to quantify human beta-defensins (h beta D-1 and h beta D-2) in saliva samples of patients with oral diseases such as lichen planus (n = 10), Behcet (n = 10) and recurrent apthous stomatitis (n = 10). Results: Linear calibration range for h beta D-1 and h beta D-2 defensins was 1.67-200 mu g mL(-1) and 3.13 - 100 mu g mL(-1) with R-2 values of 0.9998 and 0.996, correspondingly. The concentration of beta-defensins in saliva was determined by comparing the peak areas of eluted h beta D-1 and h beta D-2 with that of their standards. The variation of the amount of beta-defensins was evaluated by comparisons of the results obtained from the patients with oral mucosal diseases before and after treatments and the control subjects. The limit of detection (LOD) and limit of quantification (LOQ) were found to be 1.62 mu g mL(-1) and 5.39 mu g mL(-1) for h beta D-1 and 0.94 mu g mL(-1) and 3.13 mu g mL(-1) for h beta D-2, respectively. Conclusion: The salivary beta-defensin concentration was significantly higher in patients with oral mucosal diseases than in healthy volunteers; furthermore, in patients with oral mucosal diseases, the concentration was significantly higher before treatment than after treatment.eninfo:eu-repo/semantics/closedAccessDefensinh beta D-1h beta D-2high-performance liquid chromatography (HPLC)oral diseasesalivaArticle62323023824564045WOS:000329085600013Q4